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Background-—Although clopidogrel reduces the incidence of atherothrombotic events, its use is associated with an increased risk
of major bleeding. Cerebral microbleeds (CMBs) are indicative of subclinical microangiopathy in the brain and may prelude
symptomatic intracerebral hemorrhage. We examined the association between use of clopidogrel and CMBs in persons without a
history of stroke.
Methods and Results-—We performed a cross-sectional analysis using data from the Rotterdam Study, a prospective
population-based cohort of persons aged 45 years and older. Among 4408 stroke-free individuals who underwent brain magnetic
resonance imaging for the detection of CMBs, we identiﬁed 121 ever-users and 4287 never-users of clopidogrel before magnetic
resonance imaging. We used multiple logistic regression to analyze the association between clopidogrel and CMBs with adjustment
for age, sex, cardiovascular risk factors, and common cardiovascular medication. Users of clopidogrel had a higher prevalence of
CMBs (odd ratio 1.55, 95% CI 1.01 to 2.37) than nonusers and more often had a high number (>4) of CMBs (odds ratio 3.19, 95%
CI 1.52 to 6.72). Clopidogrel use was associated with a signiﬁcantly higher prevalence of deep or infratentorial CMBs (odd ratio
1.90, 95% CI 1.05 to 3.45). Among clopidogrel users, we were unable to demonstrate differences in the prevalence of CMBs by
indication of prescription, history of coronary heart disease, or common genetic variants in CYP2C19.
Conclusions-—In stroke-free individuals, clopidogrel use was associated with a higher prevalence and higher number of CMBs.
Whether this association is causal requires conﬁrmation in prospective studies, especially given the small number of participants
taking clopidogrel and the possibility of residual confounding in this study. ( J Am Heart Assoc. 2013;2:e000359 doi: 10.1161/
JAHA.113.000359)
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C lopidogrel is a commonly prescribed antiplatelet drug,especially during and after percutaneous coronary
interventions (PCIs).1,2 The addition of clopidogrel to aspirin
monotherapy reduces the recurrence of atherothrombotic
events.3 Despite its considerable clinical beneﬁt, clopidogrel
use is also associated with an increased risk of major
bleeding.4 To date, there is still a gap in knowledge on
subclinical bleeds under clopidogrel use.
Cerebral small-vessel disease is a common ﬁnding in
elderly individuals5, and cerebral microbleeds (CMBs) on
magnetic resonance imaging (MRI) are a relatively newly
recognized marker of the condition.6 CMBs rarely disappear
once they are present7, and the presence of CMBs has been
associated with prevalence and severity of spontaneous
intracerebral hemorrhage.8 In addition, the presence of CMBs
may predict future occurrence or recurrence of intracerebral
hemorrhage.9,10
We hypothesized that CMBs occur more often in persons
using clopidogrel and studied the association among clopido-
grel, CYP2C19 genotype, and CMBs in a large popula-
tion-based cohort study.
Methods
Study Population
This cross-sectional analysis of CMB occurrence was part of
the Rotterdam Scan Study, an ongoing population-based
cohort study investigating age-related brain changes on MRI
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within the larger Rotterdam Study.11,12 At the time of this study,
a total of 5990 participants of the Rotterdam Study had at least
once been invited to undergo a scan. Of these, 5449
participants were eligible, of whom 5007 participated and gave
written consent (response rate 91.9%). After the exclusion of
subjects with physical inabilities to complete an MRI examina-
tion, scans of 4930 subjects were obtained between 2005 and
2011, of which 34 images had to be excluded because of
artifacts, leaving 4896 images to be analyzed.
Given the cross-sectional design of this study, it was
impossible to assess whether a stroke or a CMB occurred ﬁrst
in the study participants in whom both were present on MRI.
Both ischemic and hemorrhagic stroke are associated with an
increased prevalence of CMBs.13 Because an ischemic stroke
can be an indication for use of clopidogrel,14 the inclusion of
persons with an ischemic stroke could lead to a spurious
overestimate of the effect of the association between
clopidogrel use and CMBs. Hemorrhagic stroke can be a
contraindication for antithrombotic drug prescription,15 so the
inclusion of patients with such a condition could spuriously
dilute the association between clopidogrel use and CMBs.
Consequently, we excluded all persons with an MRI-deﬁned
hemorrhagic or ischemic stroke (n=488), leaving a study
population of 4408 participants. The Rotterdam Study was
approved by the Medical Ethics Committee of the Erasmus
Medical Center, Rotterdam, the Netherlands. All participants
provided written informed consent to participate in the study.
Brain MRI and CMBs
All participants underwent a multisequence MRI protocol
using a 1.5-T scanner (GE Healthcare), which included a
custom-made accelerated 3-dimensional T2*-weighted gradi-
ent-recalled echo (3-dimensional T2* GRE) sequence with
high spatial resolution and long echo time was used for CMB
detection.16 All scans were reviewed by experienced raters for
the presence, number, and location of CMBs, which were
deﬁned as focal areas of very low signal intensity that were
not accompanied by evident signal abnormality on other
structural sequences.6 All raters were blinded to the clinical
data and genotype, and intraobserver and interobserver
reliabilities for CMB rating were very good (j=0.85 to
0.87).17 As previously done by others,18,19 CMB location
was classiﬁed as lobar (cortical gray matter and subcortical or
periventricular white matter), deep (deep gray matter: basal
ganglia and thalamus, and the white matter of the corpus
callosum, internal, external, and extreme capsule), or infra-
tentorial (brainstem and cerebellum). CMBs in deep or
infratentorial locations are believed to be suggestive of
hypertensive or atherosclerotic microangiopathy,20 whereas
those occurring in strictly lobar brain sites are indicative of
cerebral amyloid angiopathy.21
Pharmacy Data
Nearly all participants of the Rotterdam Study are registered
at 1 or more of the 7 community pharmacies that serve the
study area.12 As of January 1, 1991, complete records of all
outpatient dispensed prescriptions of these pharmacies have
been available in automated format, and concordance
between pharmacy dispense records and patient interview
data is strong.22 Records include the product name, interna-
tional nonproprietary name, Anatomical Therapeutic Chemical
(ATC) code,23 prescribed daily number of units, date of
delivery, drug dosage, and the total number of delivered
units,24 the latter of which was used to determine cumulative
exposure to clopidogrel. We used ATC codes B01AA, B01AB,
B01AC, and B01AX for antithrombotic agent use (of which
B01AC04 represents clopidogrel); C02, C03, C07, C08, and
C09 for antihypertensive medication; and C10 for lipid-mod-
ifying medication.
Covariables, Medical History and CYP2C19
At every regular visit of study participants to the Rotterdam
Study research center, information on cardiovascular risk
factors was obtained through interview, laboratory and
physical examination.25 A known history of myocardial infarc-
tion was assessed on entry of study participants into the
Rotterdam Study and, subsequently, participants have been
continuously monitored for incident myocardial infarction
through automated linkage of the study database with ﬁles
from general practitioners and hospital discharge information.
For all cases, subsequent validation by research physicians
and medical specialists was performed on the basis of clinical
details from medical records as described earlier.25
As a prodrug, clopidogrel is activated by several hepatic
enzymes, including cytochrome P450 subfamily 2C19
(CYP2C19); common variation in the CYP2C19 gene alters
enzyme activity and thereby platelet reactivity to clopido-
grel.26,27 As a result, individuals with at least 1 CYP2C19*2
(681G>A, rs4244285) variant allele have a lower risk of
bleeding,28 whereas the CYP2C19*17 (806C>T, rs12248560)
variant is associated with a higher risk of major bleeding.29 As
previously described in detail,12 the Illumina HumanHap 550k
and 610-Quad arrays were used in the majority of participants
of the Rotterdam Study to perform genotyping of autosomal
SNPs. This included genotyping the rs12767583 and
rs12243416 variants, which are, respectively, in complete
linkage disequilibrium (r2=1.0) with rs4244285 (CYP2C19*2)
and rs12248560 (CYP2C19*17). Within clopidogrel users, we
distinguished persons with at least 1 *2 allele (the *2 group),
persons with at least 1 *17 allele (the *17 group), and
wild-type homozygotes (deﬁned by the absence of *2 and *17
variants). We hypothesized that CMB prevalence and number
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would be lower in persons with a CYP2C19*2 variant allele
than in wild-type homozygotes and higher in persons with a
CYP2C19*17 variant allele.
Data Analysis
We used multiple logistic regression analyses to calculate
odds ratios (ORs) for the prevalence of CMBs in ever-users
and never-users of clopidogrel before MRI, both overall and
per brain location category (“strictly lobar” and “deep or
infratentorial”). We also investigated the association of
clopidogrel with the number of CMBs, both as a continuous
(linear regression) and a categorical outcome measure
(multinomial logistic regression). Based on the left-skewed-
ness of the distribution of the number of CMBs in the general
population,30,31 we categorized the number of CMBs into 1, 2
to 4, and >4 and used CMB-free individuals as the reference
category. In a separate analysis, we compared the prevalence
of CMBs between individuals who only used salicylates,
individuals who used both salicylates and clopidogrel, and
individuals who used neither.
All analyses were performed twice using complete-case
data: in the ﬁrst model, adjustments were made for age and
sex. For the second model, we adjusted additionally for
traditional cardiovascular risk factors and cardiovascular
medication: smoking (current, former, never), systolic and
diastolic blood pressure, diabetes mellitus, total and high-den-
sity lipoprotein cholesterol, use of antihypertensive medica-
tion, use of lipid-modifying medication, and use of any
antithrombotic agent other than clopidogrel. Also, we con-
secutively repeated model II analyses by adding duration of
clopidogrel use as a categorical determinant (per 3 months of
cumulative use, highest category >18 months) and separately
adding the ﬁrst prescription indication for clopidogrel as a
categorical variable (PCI, other intervention, no intervention).
Also, we added history of myocardial infarction into the model
and studied the interaction term of myocardial infarction and
use of clopidogrel in our study population. We repeated this
analysis for a history of any coronary heart disease (myocar-
dial infarction, PCI, or surgical coronary artery bypass graft
surgery).
To assess the inﬂuence of CYP2C19 in clopidogrel users,
we compared CMB prevalence and number in the *2 group
with wild-type homozygotes and the *17 group with wild-type
homozygotes. We used a commercially available software
program (IBM SPSS Statistics for Windows, Version 20.0).
Results
Study population characteristics at the time of the scan are
presented in Table 1. The mean age of the population was
63.6 years (age range 45.7 to 96.3 years), and 2136 (48.5%)
were women. There were 121 persons (2.7%) who had used
clopidogrel before MRI, 111 of whom had also used a
salicylate. First prescription dose was available for 83 (68.6%)
clopidogrel users; in all of these individuals, the same dose
was prescribed (75 mg once daily). The association between
clopidogrel use and the presence and location of CMBs is
shown in Table 2. Users of clopidogrel had a higher preva-
lence of CMBs than nonusers of clopidogrel (adjusted OR for
users compared with nonusers 1.55, 95% CI 1.01 to 2.37).
Clopidogrel use was signiﬁcantly associated with a higher
prevalence of CMBs in deep or infratentorial locations (OR
1.90, 95% CI 1.05 to 3.45), but not with CMBs in strictly lobar
locations (OR 1.34, 95% CI 0.81 to 2.21). Clopidogrel users
had an average number of 1.6 CMBs, while non-users on
average had 0.5 CMBs (P=0.01). The distribution of number of
CMBs according to clopidogrel ever-use is shown in Figure.
Clopidogrel use was signiﬁcantly associated with presence of
more than 4 CMBs (OR 3.19, 95% CI 1.52 to 6.72), but not
with presence of 1 CMB (OR 1.35, 95% CI 0.79 to 2.31) and 2
to 4 CMBs (OR 1.14, 95% CI 0.55 to 2.36).
The multivariate model had reasonable discriminative
ability for the presence of CMBs in any location (c-statistic
0.69, 95% CI 0.67 to 0.71), strictly lobar locations (c-statistic
0.67, 95% CI 0.65 to 0.70), and deep or infratentorial
locations (95% CI 0.73 to 0.79). The overall calibration of
the model was good for the presence of any CMB (Hosmer-
Lemeshow goodness-of-ﬁt statistic v2=9.66, P=0.29), strictly
lobar CMBs (v2=11.84, P=0.16), and deep or infratentorial
CMBs (v2=5.71, P=0.68).
We found no evidence of effect modiﬁcation between
clopidogrel use and history of myocardial infarction (P=0.35).
The OR for clopidogrel use was 1.63 (95% CI 0.93 to 2.88) in
persons without a history of myocardial infarction and 1.03
(95% CI 0.49 to 2.15) in persons with a history of myocardial
infarction. Similarly, we could not demonstrate effect modi-
ﬁcation between clopidogrel and a history of any coronary
heart disease (P=0.44). In individuals without a history of
coronary heart disease, those who used clopidogrel had an
OR of 1.39 (95% CI 0.49 to 3.91); in individuals with a history
of coronary heart disease, clopidogrel users had an OR of
0.76 (95% CI 0.43 to 1.35).
Within clopidogrel users, duration of use was not associ-
ated with a difference in prevalence (P=0.64) or number of
CMBs (P=0.89). The indication for the ﬁrst prescription
of clopidogrel was retrieved in 104 clopidogrel users; in 87 of
those a PCI was the indication. There was no signiﬁcant
difference in prevalence of CMBs between participants with a
PCI as the ﬁrst indication and participants with other
indications (P=0.43).
Also, exclusion of ever-users of anticoagulants (n=435) did
not affect the effect size of the association between
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clopidogrel use and prevalence of CMBs, although the
association was no longer signiﬁcant (OR 1.54, 95% CI 0.94
to 2.54). The prevalence of CMBs among ever- users of both
clopidogrel and salicylates was 37.8% compared with 14.3% in
never-users of clopidogrel and salicylates (OR 2.21, 95% CI
1.41 to 3.48) and 26.4% in ever-users of salicylates only (OR
1.42, 95% CI 0.90 to 2.23; of note, salicylate use as a
covariate was removed from model II for this analysis).
A total of 97 (80.2%) clopidogrel ever-users could be
placed in 1 of the 3 CYP2C19 groups. The *2 group had no
signiﬁcantly different prevalence than wild-type homozygotes
of CMBs in any location (OR 0.91, 95% CI 0.30 to 2.75),
strictly lobar locations (OR 0.76, 95% CI 0.20 to 2.83), and
deep or infratentorial locations (OR 1.25, 95% CI 0.26 to
6.03). The *17 group also had a similar prevalence as
wild-type homozygotes of CMBs in any location (OR 0.81, 95%
CI 0.31 to 2.08), strictly lobar locations (OR 0.64, 95% CI 0.21
to 2.00), and deep or infratentorial locations (OR 1.17, 95% CI
0.30 to 4.57). Neither *2 (P=0.12) nor *17 (P=0.32) status
was associated with an altered number of CMBs in clopidogrel
users, and *2 (P=0.35) and *17 (P=0.58) status was not
related to duration of clopidogrel use.
Table 1. Characteristics of the Study Population
Characteristic Study Population
Clopidogrel Ever Use
Yes No
No. of participants 4408 121 4287
Age, mean (SD), y 63.6 (11.0) 70.4 (11.2) 63.4 (11.0)
Women, n (%) 2136 (48.5) 69 (57.0) 2067 (48.2)
Participants with ≥1 cerebral microbleed, n (%) (%) 783 (17.8) 45 (37.2) 738 (17.2)
1 cerebral microbleed, n (%) 509 (11.5) 22 (18.2) 487 (11.4)
2 to 4 cerebral microbleeds, n (%) 204 (4.6) 10 (8.3) 194 (4.5)
>4 cerebral microbleeds, n (%) 70 (1.6) 13 (10.7) 57 (1.3)
Deep or infratentorial cerebral microbleeds, n (%) 218 (5.7) 19 (20.0) 199 (5.3)
Strictly lobar cerebral microbleeds, n (%) 565 (13.5) 26 (25.5) 539 (13.2)
Any ever use of antithrombotic drugs, n (%) 1375 (31.2) 114 (94.2) 1261 (29.4)
Ever use of aspirin and/or carbasalate calcium, n (%) 1142 (25.9) 111 (91.7) 1031 (24.0)
Ever use of anticoagulant drugs,* n (%) 435 (9.9) 32 (26.4) 403 (9.4)
Ever use of other antithrombotic drug, n (%) 11 (0.2) 0 (0.0) 11 (0.3)
Any current use of antihypertensive drugs, n (%) 1319 (29.9) 100 (82.6) 1219 (28.4)
Any current use of lipid modifying drugs, n (%) 714 (16.4) 95 (78.5) 619 (14.4)
Diabetes mellitus, n (%) 276 (6.3) 17 (14.0) 259 (6.0)
Current smoker, n (%) 879 (20.1) 24 (19.8) 855 (20.1)
Former smoker, n (%) 2147 (49.0) 79 (65.3) 2068 (48.5)
Never smoker, n (%) 1358 (31.0) 18 (14.9) 1340 (31.4)
Systolic blood pressure, mean (SD), mm Hg 138 (21) 142.3 (21.2) 137.8 (20.9)
Diastolic blood pressure, mean (SD), mm Hg 82 (11) 78.2 (9.9) 82.3 (10.8)
Total cholesterol, mean (SD), mmol/L 5.6 (1.0) 4.7 (1.1) 5.6 (1.0)
HDL-cholesterol, mean (SD), mmol/L 1.4 (0.4) 1.2 (0.3) 1.5 (0.4)
History of myocardial infarction, n (%) 169 (3.9) 53 (44.5) 116 (2.7)
History of coronary heart disease, n (%)† 258 (5.9) 99 (83.2) 159 (3.7)
Participants with ≥1 CYP2C19*2 allele, n (%) 1044 (28.4) 29 (27.4) 1015 (28.4)
Participants with ≥1 CYP2C19*17 allele, n (%) 1496 (40.6) 43 (40.6) 1453 (40.6)
Participants with both ≥1 CYP2C19*2 and ≥1 *17 allele, n (%) 265 (7.2) 9 (8.5) 256 (7.2)
Data were missing for HDL (n=69) and total (n=67) cholesterol, systolic and diastolic blood pressure (both n=23), and smoking (n=24). CYP2C19 status data were available for 3677
participants. HDL indicates high-density lipoprotein.
*This category comprises both ATC codes B01AA (oral anticoagulants) and B01AB (injectable anticoagulants).
†A history of any of the following: myocardial infarction, percutaneous coronary intervention, or surgical coronary artery bypass graft surgery.
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Discussion
In this population-based study on stroke-free persons, we
demonstrate that ever-users of clopidogrel have a higher
prevalence and more often a high number of CMBs compared
with never-users. These ﬁndings add to earlier literature that
showed that use of clopidogrel is an independent risk factor
for major bleeding,4 while CMBs might be a subclinical
reﬂection of a bleeding-prone state and as such a predictor of
hemorrhagic stroke.32 To date, the only report that presented
data on the association between clopidogrel use and CMB
prevalence was restricted to stroke patients, and clopidogrel
was associated with a nonsigniﬁcant increase in CMB
prevalence of similar magnitude (OR 2.23, 95% CI 0.57 to
8.66).33
General strengths of our study included the availability of
near-complete records on both clopidogrel use and a range of
important covariates, as well as the use of a custom-made
accelerated 3D T2* MRI sequence of the brain, which enabled
us to detect CMBs with high sensitivity.16 Some potential
limitations of this observational study should also be
discussed. First, despite a large source population, the
number of clopidogrel users was relatively small. This limitedTa
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Figure. Number of cerebral microbleeds according to clopidogrel
use. For every category of cerebral microbleed number, the reference
is no cerebral microbleeds. *Signiﬁcant difference between clopido-
grel ever-users and never-users (P<0.05) after adjustment for age,
sex, smoking, systolic and diastolic blood pressure, diabetes mellitus,
total and HDL cholesterol, antihypertensive medication, lipid-modi-
fying medication, and antithrombotic agents other than clopidogrel.
HDL indicates high-density lipoprotein
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us in performing some sensitivity analyses. For instance, after
excluding anticoagulant users, the association between
clopidogrel use and CMBs was no longer signiﬁcant. However,
the exclusion did not affect the point estimate of the
association between clopidogrel use and CMBs, which
suggests that the nonsigniﬁcance was primarily caused by a
further reduction in the number of clopidogrel users. Similarly,
although the interaction term between myocardial infarction
and clopidogrel use was nonsigniﬁcant, we may have lacked
an adequate number of clopidogrel users to demonstrate
effect modiﬁcation, especially given the apparent disparity in
ORs for clopidogrel between individuals with and individuals
without myocardial infarction. The same holds for effect
modiﬁcation by any coronary heart disease.
Second, since all participants were prescribed the same
dose of clopidogrel, no dose–effect relationship could be
studied. Therefore, we assessed whether cumulative exposure
to clopidogrel was associated with CMB presence and
number, which was not the case. A possible explanation for
this ﬁnding could be that clopidogrel causes CMBs shortly
after initiation of its use, since the steady state of clopidogrel
is typically reached within 1 week.34 If so, one would still
expect the number of CMBs to rise with increasing cumulative
duration of use. The limited number of participants ever using
clopidogrel in our study population did not allow us to
adequately study the relationship between cumulative
clopidogrel use and number of CMBs.
Third, the cross-sectional design of the study limits our
ability to draw conclusions regarding causality. Since hemo-
siderin deposits remain visible in the brain for an undeﬁned
period of time, it is possible that some of the CMBs that we
observed actually occurred before the initiation of clopidogrel
use. In addition, during or after clopidogrel use, CMBs may
still occur due to the underlying generalized atherothrombotic
state for which individuals were prescribed clopidogrel. If this
occurred, it may have led to spurious inference of the effect of
clopidogrel use due to confounding by indication, taking into
account that CMBs occur more frequently in persons at
increased cardiovascular risk and that clopidogrel is almost
exclusively prescribed in persons with a history of coronary or
cerebrovascular disease.13 Therefore, we adjusted for tradi-
tional cardiovascular risk factors and cardiovascular medica-
tion use. Moreover, we excluded participants with a history of
stroke (since both ischemic and hemorrhagic strokes are
associated with CMBs13). We still found an increased
prevalence of CMBs in the clopidogrel group. However, given
our inability to adequately perform all of the sensitivity
analyses that could have more robustly supported a causal
association between clopidogrel and CMBs, we cannot rule
out the possibility of residual confounding.
Fourth, clopidogrel is often prescribed simultaneously with
a salicylate,1,35 of which we earlier demonstrated the
association with the presence of CMBs.36 The availability of
near-complete pharmacy records of the study population
enabled us to take the use of salicylates into account. We found
that adjustment for use of salicylates and other antithrombotic
agents did not alter the association between clopidogrel use
and CMBs, while a comparison between salicylate users who
did and did not use clopidogrel showed that users of the
combination had a nonsigniﬁcantly higher CMB prevalence.
Last, although CYP2C19 genotype does not provide us with
more insight into the occurrence of atherothrombotic events
in patients using clopidogrel, there is accumulating evidence
of an effect of the CYP2C19*2 and *17 variants on the
association between clopidogrel and bleeding events.28,29 Our
sample size was probably too small to detect signiﬁcant
differences in prevalence of CMBs between CYP2C19 geno-
type groups due to relatively small effect sizes.
In our population, clopidogrel use was associated with both
strictly lobar and deepor infratentorial CMBs independent of age
and sex. After we additionally adjusted for cardiovascular risk
factors and cardiovascularmedication, only the association with
deep or infratentorial locations was still signiﬁcant, suggesting
that CMBs in clopidogrel users is related to aggravation of
underlying hypertensive microangiopathy. This is in line with
recent reports showinghigher estimates for the associationwith
deep or infrantentorial CMBs than strictly lobar CMBs of several
antithrombotic agents.33,37 In stroke medicine, the burning
questions about CMBs concern their diagnostic signiﬁcance and
whether CMBs should guide the use of antithrombotic and
thrombolytic drugs.38,39 Our clinical follow-up period was too
short to assesswhether clopidogrel userswith CMBs at baseline
were at increased risk for symptomatic intracerebral hemor-
rhage. Therefore, our ﬁndings will not directly inﬂuence clinical
practice. However, the association between clopidogrel use and
CMBs in stroke-free persons emphasizes the necessity to study
a possible cascade involving clopidogrel use, CMBs, and major
bleeding events in prospective studies.
In conclusion, we have demonstrated that in persons
without a history of stroke, use of clopidogrel is associated
with an increased prevalence of CMBs. Whether this associ-
ation is causal requires conﬁrmation in prospective studies.
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